2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylacetamide | 1092977-08-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylacetamide
• 英文别名: 2-[2-(3-butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N-dimethylacetamide；1,1-Dimethylethyl N-[2-(3-butoxyphenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]carbamate；tert-butyl N-[2-(3-butoxyphenyl)ethyl]-N-[2-(dimethylamino)-2-oxoethyl]carbamate
• CAS: 1092977-08-6
• 化学式: C₂₁H₃₄N₂O₄
• 分子量: 378.512
• InChiKey: IHADWQZJWBUJJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  59.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylacetamide 以95的产率得到2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide hydrochloride
  参考文献：
  名称：

  Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

  摘要：

  替代2-[2-(苯基)乙基氨基]脂肪酰胺衍生物、其药学上可接受的盐以及含有它们的制药组合物，可用作钠和/或钙通道调节剂，以预防、缓解和治愈上述机制发挥病理作用的病理学。这些化合物可以特别用于预防、缓解和治愈神经、认知、精神、炎症、泌尿生殖和胃肠疾病等疾病。

  公开号：

  US08519000B2
• 作为产物：
  描述：

  3-苄氧基苯乙胺盐酸盐 在 palladium 10% on activated carbon sodium hydroxide 、 氢气 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 20.0 ℃ 、241.32 kPa 条件下， 反应 121.0h， 生成 2-(2-(3-butoxyphenyl)-N-tert-butoxycarbonylethylamino)-N,N-dimethylacetamide
  参考文献：
  名称：

  WO2008/151702

  摘要：

  公开号：

文献信息

• [EN] PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRODUCTION DE DÉRIVÉS DE 2-[2-(PHÉNYL)ÉTHYLAMINO]ALCANEAMIDE SUBSTITUÉS
  申请人：NEWRON PHARM SPA

  公开号：WO2020212227A1

  公开（公告）日：2020-10-22

  The present invention relates to a new process for the production of substituted 2-[2-(phenyl) ethylaminojalkaneamide derivatives of the following formula (I), in particular 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide in high yields with very high chemical purity. The invention relates to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof:

  本发明涉及一种用于生产以下式(I)的取代2-[2-(苯基)乙基氨基烷酰衍生物的新工艺，特别是高产率、化学纯度非常高的2-[2-(3-丁氧基苯基)-乙基氨基]-N,N-二甲基乙酰胺。该发明涉及一种制备式(I)化合物或其药用可接受盐的工艺：
• SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS
  申请人：Melloni Piero

  公开号：US20100210631A1

  公开（公告）日：2010-08-19

  Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly used for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital, and gastrointestinal diseases.

  2-[2-(苯基)乙基氨基]烷酰胺衍生物及其药用盐以及含有它们的药物组合物可用作钠和/或钙通道调节剂，用于预防、缓解和治疗上述机制发挥病理作用的病变。这些化合物特别可用于预防、缓解和治疗例如神经、认知、精神、炎症、泌尿生殖以及胃肠疾病等病症。
• PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP3725768A1

  公开（公告）日：2020-10-21

  The present invention relates to a new process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives of the following formula (I), in particular 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide in high yields with very high chemical purity The invention relates to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof:

  本发明涉及一种生产下式（I）的取代的 2-[2-（苯基）乙基氨基]烷酰胺衍生物的新工艺，特别是高产率和极高化学纯度的 2-[2-（3-丁氧基苯基）-乙基氨基]-N,N-二甲基乙酰胺。 本发明涉及一种制备式（I）化合物或其药学上可接受的盐的工艺：
• PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：US20220185766A1

  公开（公告）日：2022-06-16

  The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C 3 -C 10 )alkyl, or ω-trifluoro(C 3 -C 10 )alkyl; R 1 and R 2 are, independently, hydrogen, hydroxy, (C 1 -C 8 ) alkoxy, (C 1 -C 8 ) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R 1 and R 2 is in ortho position to the R—O— group and, taken together with the same R—O—, represents a Formula (A) group where R 0 is (C 2 -C 9 )alkyl; R 3 and R 4 are, independently, hydrogen, (C 1 -C 4 )alkyl; or R 4 is hydrogen and R 5 is a group selected from —CH 2 —OH, —CH 2 —O—(C 1 -C 6 )alkyl, —CH(CH 3 )—OH, —(CH 2 ) 2 —S—CH 3 , benzyl and 4-hydroxybenzyl; or R 4 and R 5 , taken together with the adjacent carbon atom, form a (C 3 -C 6 )cycloalkyl residue; R 5 and R 6 are independently hydrogen or (C 1 -C 6 )alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among —O—, —S— and —NR 7 — where R 7 is hydrogen or (C 1 -C 6 ) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , preferably in the R group, can be substituted by a deuterium atom.